Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.
Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening
Body weight between 50.0 kg and 90.0 kg, inclusive, and body mass index (BMI) between 18.5 kg/m² and 29.9 kg/m², inclusive, at the time of screening (BMI = weight [kg] / height [m]²)
For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration Other exclusions applied
6
Treatment groupsSee each treatment group below.